OLMA Olema Pharmaceuticals, Inc.
Financings ·
Olema is selling 19,928,875 shares at $9.08 and pre-funded warrants for 7,604,163 shares. Novartis will supply ribociclib for the planned Phase 3 OPERA-02 trial.
We have not published a story on Olema Pharmaceuticals yet. When there is news, it will appear here.
Olema Pharmaceuticals is a clinical-stage biopharmaceutical company developing next-generation targeted therapies for breast cancer and beyond, with a focus on endocrine-driven cancers, nuclear receptors and mechanisms of acquired resistance. Its lead product candidate, palazestrant (formerly OP-1250), is an oral small molecule with dual activity as a complete estrogen receptor antagonist and selective estrogen receptor degrader, investigated in ER-positive, HER2-negative breast cancer. Across more than 400 patients in clinical studies, the company reports strong anti-tumor activity and favorable tolerability. The pivotal Phase 3 OPERA-01 trial tests palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer. The pivotal Phase 3 OPERA-02 trial tests palazestrant with ribociclib in front-line metastatic disease, supported by a clinical trial collaboration and supply agreement with Novartis Pharma AG. Palazestrant is also in Phase 1/2 studies combined with CDK4/6 inhibitors, alpelisib, everolimus and atirmociclib. The second clinical candidate, OP-3136, is an oral KAT6 inhibitor in a Phase 1 trial. Olema relies on third parties for manufacturing.
| Product or program | What it is | Stage |
|---|---|---|
| palazestrant (OP-1250) | Oral dual ER antagonist and degrader for ER-positive, HER2-negative breast cancer | Phase 3 (OPERA-01 and OPERA-02) |
| OP-3136 | Oral KAT6 inhibitor for breast and other solid tumors | Phase 1, enrolling patients |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $157.7 million | $124.5 million |
| Net income (loss) | -$162.5 million | -$129.5 million |
| Cash from operations | -$146.7 million | -$104.4 million |
| Cash and equivalents | $48.3 million | $139.5 million |
| Short-term investments | $457.1 million | $294.6 million |
Our latest story on this, dated Dec 2, 2024: "Olema Oncology announces $250.0 million private placement and Novartis supply deal". The story links the filing or release it is based on. Read the story.
Olema Pharmaceuticals, Inc. trades under the ticker OLMA on NASDAQ.
Olema Pharmaceuticals, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Olema Pharmaceuticals, Inc. is 1750284. Its filings are on SEC EDGAR.
87,497,607 shares as of 2026-08-06, per the cover page of its 10-Q filed 2026-08-10.
Our directory records Olema Pharmaceuticals, Inc. under United States.
Our directory classifies Olema Pharmaceuticals, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Olema Pharmaceuticals, Inc. is US68062P1066.
aibio.space lists Olema Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Olema Pharmaceuticals is a clinical-stage biopharmaceutical company developing next-generation targeted therapies for breast cancer and beyond, with a focus on endocrine-driven cancers, nuclear receptors and mechanisms of acquired resistance. Its lead product candidate, palazestrant (formerly OP-1250), is an oral small molecule with dual activity as a complete estrogen receptor antagonist and selective estrogen receptor degrader, investigated in ER-positive, HER2-negative breast cancer.
palazestrant (OP-1250): Oral dual ER antagonist and degrader for ER-positive, HER2-negative breast cancer Stage: Phase 3 (OPERA-01 and OPERA-02).
OP-3136: Oral KAT6 inhibitor for breast and other solid tumors Stage: Phase 1, enrolling patients.
Olema Pharmaceuticals, Inc. reported a net loss of $162.5 million for the fiscal year ended Dec 31, 2025, and used $146.7 million of cash in operations, per its annual report to the SEC.
$157.7 million in the fiscal year ended Dec 31, 2025, per its annual report.
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.02,7.01,9.01). Source
Set up an at-the-market program to sell shares over time. SEC Form S-3ASR. Source
Reported a financing. SEC Form 8-K (Items 8.01). Source
Reported an unregistered sale of its securities. SEC Form S-3. Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio